Researchers Deform Cells to Deliver RNA, Proteins, and Nanoparticles for Many Applications
|
By LabMedica International staff writers Posted on 06 Feb 2013 |

Image: As cells squeeze through a narrow channel, tiny holes open in their membranes, allowing large molecules such as RNA to pass through (Photo courtesy of Armon Sharei and Emily Jackson).
Researchers have found a safe and effective way to push large molecules through the cell membrane by jamming the cells through a narrow constriction that opens up very small, temporary holes in the membrane. Any large molecules drifting outside the cell—such as proteins, RNA, or nanoparticles—can slide through the membrane during this disruption.
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Latest BioResearch News
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







